2-(1-Methylethyl)-4-propylthiazole | 87116-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1-Methylethyl)-4-propylthiazole
• 英文别名: 2-propan-2-yl-4-propyl-1,3-thiazole
• CAS: 87116-69-6
• 化学式: C₉H₁₅NS
• 分子量: 169.29
• InChiKey: RQVTUZSNNLPWLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2015078374A1

  公开（公告）日：2015-06-04

  The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其药用盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• [EN] VIRAL POLYMERASE INHIBITORS<br/>[FR] INHIBITEURS DE POLYMERASE VIRALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009018656A1

  公开（公告）日：2009-02-12

  Compound of Formula I: wherein, R2, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase

  化合物的化学式I：其中，R2、R5和R6如本文所定义，可用作乙型肝炎病毒NS5B聚合酶的抑制剂。
• TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS
  申请人：Crosignani Stefano

  公开号：US20120115895A1

  公开（公告）日：2012-05-10

  The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases. The compounds according to Formula (I) are suitable as modulators of CRTH2. The invention provides Spiro derivatives according to Formula (I) and related formulae that are useful in the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, and inflammatory dermatoses such as atopic dermatitis, contact hypersensitivity, allergic contact dermatitis, chronic urticaria/chronic idiopathic/autoimmune urticaria, drag-induced exanthems (e.g., toxic epidermal necrolysis or Lyell's syndrome/Stevens-Johnson syndrome/drug hypersensitivity syndrome), photodermatosis or polymorphous light emption (e.g., photoirritant contact dermatitis, photoallergy contact dermatitis, chronic actinic dermatitis), and myositis neurodegenerative disorders such as neuropatic pain and other diseases with an inflammatory component such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD).

  本发明涉及式（I）的化合物作为药物活性化合物的用途，以及含有该化合物的药物制剂，用于治疗过敏性疾病。根据式（I）的化合物适用于CRTH2的调节剂。本发明提供了根据式（I）及相关式的螺环衍生物，其在过敏性疾病（如过敏性哮喘、过敏性鼻炎、过敏性结膜炎）以及炎症皮肤病（如特应性皮炎、接触性超敏性、过敏性接触性皮炎、慢性荨麻疹/慢性特发性/自身免疫性荨麻疹、药物诱发性皮疹（如毒性表皮坏死症或Lyell综合征/史蒂文斯-约翰逊综合征/药物过敏综合征）、光敏皮肤病或多形性光敏反应（如光致刺激性接触性皮炎、光致过敏接触性皮炎、慢性光性皮炎））以及肌炎神经退行性疾病（如神经病性疼痛）和其他具有炎症成分的疾病（如类风湿性关节炎、多发性硬化症、骨关节炎和炎症性肠病（IBD））的治疗和/或预防中有用。
• DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS
  申请人：North & South Brother Pharmacy Investment Company Limited

  公开号：EP3122747B1

  公开（公告）日：2020-05-20
• MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
  申请人：Gilead Sciences, Inc.

  公开号：US20180221348A1

  公开（公告）日：2018-08-09

  The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.